Russia (bbabo.net), - A drug for the treatment of coronavirus based on monoclonal antibodies, which is being developed by specialists from the Gamaleya Center, is also effective against the omicron strain. This was stated by the director of the center Alexander Gintsburg.

"The set of monoclonal antibodies has been tested on the omicron and works very well," RIA Novosti quotes the scientist. Gunzburg added that after the New Year holidays, it is planned to begin clinical trials of a new drug. The research will take three months.

Earlier, Gunzburg named the main danger of the omicron strain for Russia. According to him, "omicron" can exert great pressure on the country's health care system. The fact is that the new strain is spreading very quickly. As a result, the number of cases, primarily among the unvaccinated, can reach very high values, and "the health care system, bed capacity, will no longer cope with all the ensuing consequences for the sick and for clinical hospitals."

bbabo.Net